COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are still working primarily from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

While continuing to address COVID-19, it is critical that we support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $361 million in 92 projects around the world.











focused on new classes


The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More

Spotlight on Science

Vedanta Biosciences’ new VE303 drug will prevent live-threatening C. difficile infections by boosting the body’s microbiome

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video




UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners




Newry, ME

Gordon Research Conference: Staphylococcal Diseases



The World Economic Forum Special Annual Meeting - 2021 Singapore



Global Conference on Vaccines Research and Development


  • 07.29.2021  |  CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria full release

  • 06.08.2021  |  CARB-X is funding Accelerate Diagnostics to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections full release

  • 06.01.2021  |  CARB-X is funding Swiss pharma company BioVersys to develop a new class of antibiotics to treat infections caused by multidrug-resistant ESKAPE pathogens full release

See All News

In The News

  • 07.14.2021  |  Bugworks in the spotlight full story

  • 05.27.2021  |  Striving to bolster the antibiotic pipeline before it becomes the next crisis full story

  • 05.05.2021  |  Mutabilis’ EBL-1463 programme graduates from ENABLE with Development Candidate and continues to progress with funding and support from CARB-X full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.